Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | Can we improve on R-CHOP for the frontline treatment of DLBCL?

Georg Lenz • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Polatuzumab vedotin
POLARIX

Can we improve on R-CHOP for the treatment of diffuse large B-cell lymphoma (DLBCL)? Georg Lenz, MD, University of Münster, Münster, Germany, discusses this question at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Georg Lenz

Update from the Lenz lab in Münster 1:29
Update from the Lenz lab in Münster
Georg Lenz • 20 Jun 2019
DLBCL research to watch 0:55
DLBCL research to watch
Georg Lenz • 20 Jun 2019
The unmet need in DLBCL 0:43
The unmet need in DLBCL
Georg Lenz • 18 Apr 2016
The importance of recgonizing different DLBCL subtypes 1:08
The importance of recgonizing different DLBCL subtypes
Georg Lenz • 9 Jun 2016

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals